IDEXX Laboratories EBITDA vs. Shares Outstanding
IX1 Stock | EUR 400.70 5.50 1.39% |
For IDEXX Laboratories profitability analysis, we use financial ratios and fundamental drivers that measure the ability of IDEXX Laboratories to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well IDEXX Laboratories utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between IDEXX Laboratories's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of IDEXX Laboratories over time as well as its relative position and ranking within its peers.
IDEXX |
IDEXX Laboratories Shares Outstanding vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining IDEXX Laboratories's current stock value. Our valuation model uses many indicators to compare IDEXX Laboratories value to that of its competitors to determine the firm's financial worth. IDEXX Laboratories is currently regarded as number one stock in ebitda category among its peers. It also is currently regarded as number one stock in shares outstanding category among its peers creating about 0.08 of Shares Outstanding per EBITDA. The ratio of EBITDA to Shares Outstanding for IDEXX Laboratories is roughly 12.20 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the IDEXX Laboratories' earnings, one of the primary drivers of an investment's value.IDEXX Shares Outstanding vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
IDEXX Laboratories |
| = | 1.01 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
IDEXX Laboratories |
| = | 82.9 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
IDEXX Shares Outstanding Comparison
IDEXX Laboratories is currently under evaluation in shares outstanding category among its peers.
IDEXX Laboratories Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in IDEXX Laboratories, profitability is also one of the essential criteria for including it into their portfolios because, without profit, IDEXX Laboratories will eventually generate negative long term returns. The profitability progress is the general direction of IDEXX Laboratories' change in net profit over the period of time. It can combine multiple indicators of IDEXX Laboratories, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine. IDEXX Laboratories operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange. It employs 8000 people.
IDEXX Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on IDEXX Laboratories. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of IDEXX Laboratories position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the IDEXX Laboratories' important profitability drivers and their relationship over time.
Use IDEXX Laboratories in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if IDEXX Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IDEXX Laboratories will appreciate offsetting losses from the drop in the long position's value.IDEXX Laboratories Pair Trading
IDEXX Laboratories Pair Trading Analysis
The ability to find closely correlated positions to IDEXX Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace IDEXX Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back IDEXX Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling IDEXX Laboratories to buy it.
The correlation of IDEXX Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as IDEXX Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if IDEXX Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for IDEXX Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your IDEXX Laboratories position
In addition to having IDEXX Laboratories in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Communication Thematic Idea Now
Communication
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Communication theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Communication Theme or any other thematic opportunities.
View All Next | Launch |
Additional Information and Resources on Investing in IDEXX Stock
When determining whether IDEXX Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IDEXX Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Idexx Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Idexx Laboratories Stock:Check out Risk vs Return Analysis. For more detail on how to invest in IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
To fully project IDEXX Laboratories' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of IDEXX Laboratories at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include IDEXX Laboratories' income statement, its balance sheet, and the statement of cash flows.